Picrorhiza scrophulariiflora improves accelerated atherosclerosis through inhibition of redox-sensitive inflammation

International Journal of Cardiology

Volumn 136, Issue 3, 2009, Pages 315-324

  Guo, Zhi Jian ^a   Hou, Fan Fan ^a   Liu, Shang Xi ^a   Tian, Jian Wei ^a   Zhang, Wei Ru ^a   Xie, Di ^a   Zhou, Zhan Mei ^a   Liu, Zhi Qiang ^a   Zhang, Xun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Accelerated atherosclerosis; Advanced glycation end products; Advanced oxidation protein products; Picrorhiza scrophulariiflora

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; GLUTATHIONE PEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PICRORHIZA SCROPHULARIIFLORA EXTRACT; PLANT EXTRACT; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA ATHEROSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; EXPERIMENTAL RABBIT; FEMALE; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PICRORHIZA KURROA; PICRORHIZA SCROPHULARIIFLORA; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

ANIMALS; AORTIC DISEASES; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; FEMALE; GLUTATHIONE PEROXIDASE; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; OXIDATIVE STRESS; PICRORHIZA; RABBITS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68049113275     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.12.102     Document Type: Article

References (42)

1. Stirban A.O., and Tschoepe D. Cardiovascular complications in diabetes: targets and interventions. Diabetes Care 31 Suppl 2 (2008) S215-S221
2. Ansari A., Kaupke C.J., Vaziri N.D., Miller R., and Barbari A. Cardiac pathology in patients with end-stage renal disease maintained on hemodialysis. Int J Artif Organs 16 (1993) 31-36
3. Reusch J.E., and Draznin B.B. Atherosclerosis in diabetes and insulin resistance. Diabetes Obes Metab 9 (2007) 455-463
4. Sarnak M.J. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 41 (2003) 11-17
5. Kalousova M., Skrha J., and Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 51 (2002) 597-604
6. Martin-Gallan P., Carrascosa A., Gussinye M., and Dominguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 34 (2003) 1563-1574
7. Kaneda H., Taguchi J., Ogasawara K., Aizawa T., and Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 162 (2002) 221-225
8. Vlassara H., Fuh H., Donnelly T., and Cybulsky M. Advanced glycation end products promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1 (1995) 447-456
9. Wendt T., Harja E., Bucciarelli L., et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 185 (2006) 70-77
10. Bro S., Bentzon J.F., Falk E., Andersen C.B., Olgaard K., and Nielsen L.B. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol 14 (2003) 2466-2474
11. Liu S.X., Hou F.F., Guo Z.J., et al. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26 (2006) 1156-1162
12. Meerwaldt R., Hartog J.W., Graaff R., et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16 (2005) 3687-3693
13. Yang X.B., Hou F.F., Wu Q., et al. Increased levels of advanced oxidation protein products are associated with atherosclerosis in chronic kidney disease. Zhonghua Nei Ke Za Zhi 44 (2005) 342-346
14. Drueke T., Witko-Sarsat V., Massy Z., et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106 (2002) 2212-2217
15. Zhang H.L., Hsia K.C., and Lou T.C. Botanical and pharmacognostical studies of the Chinese drug hu-huang-lien, rhizome picrorrhizae. Acta Pharm Sinica 12 (1965) 808-816
16. Yang J., Li P., Zhang Y.M., and Liu P. The pharmacological effect of Picrohiza. Pharm J Chinese People's Liberation Army 19 (2003) 217-218
17. Luper S. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev 3 (1998) 410-421
18. Smit H.F., Kroes B.H., van den Berg A.J., et al. Immunomodulatory and anti-inflammatory activity of Picrorhiza scrophulariiflora. J Ethnopharmacol 73 (2000) 101-109
19. Chander R., Kapoor N.K., and Dhawan B.N. Picroliv, picroside-I and kutkoside from Picrorhiza kurrooa are scavengers of superoxide anions. Biochem Pharmacol 44 (1992) 180-183
20. Li J.T., Hou F.F., Guo Z.J., Shan Y.X., Zhang X., and Liu Z.Q. Advanced glycation end products upregulate C-reactive protein synthesis by human hepatocytes through stimulation of monocyte IL-6 and IL-1 beta production. Scand J Immunol 66 (2007) 555-562
21. Li H.Y., Hou F.F., Zhang X., et al. Advanced oxidation protein products accelerate renal fibrosis in a remnant kidney model. J Am Soc Nephrol 18 (2007) 528-538
22. Hou F.F., Boyce J., Chertow G.M., Kay J., and Owen Jr. W.F. Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin. J Am Soc Nephrol 9 (1998) 277-283
23. Witko-Sarsat V., Friedlander M., Nguyen K.T., et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161 (1998) 2524-2532
24. Guo Z.J., Hou F.F., Liu S.X., Zhang W.R., Zhou Z.M., and Liu Z.Q. Proteins modified with glycation or oxidation products accelerate atherosclerosis in experimental hypercholesterolemic rabbits. Beijing Da Xue Xue Bao 36 (2004) 127-130
25. Hou F.F., Ren H., Owen Jr. W.F., et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 15 (2004) 1889-1896
26. Lehr H.A., Sagban T.A., Ihling C., et al. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 104 (2001) 914-920
27. Zhou M., Chen Y., Yan D.G., et al. Preparation and characterization of two monoclonal antibodies against oxidatively modified low density lipoprotein (O-LDL) and detection of O-LDL in serum in patients with coronary heart disease. Med Sci Res 25 (1997) 445-449
28. Shi Z.R., Itzkowitz S.H., and Kim Y.S. A comparison of three immunoperoxidase techniques for antigen detection in colorectal carcinoma tissues. J Histochem Cytochem 36 (1988) 317-322
29. Shen H., and Lu Y.D. Study on the quantitative method of immunohistochemistry. J Biomed Eng 10 (1993) 281-284
30. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 15 (1976) 212-216
31. Flohe L., and Gunzler W.A. Assays of glutathione peroxidase. Methods Enzymol 105 (1984) 114-121
32. Basta G., Lazzerini G., Massaro M., et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105 (2002) 816-822
33. Minuz P., Fava C., and Cominacini L. Oxidative stress, antioxidants, and vascular damage. Br J Clin Pharmacol 61 (2006) 774-777
34. Kunsch C., and Medford R.M. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 85 (1999) 753-766
35. Stenvinkel P., Pecoits-Filho R., and Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 14 (2003) 1927-1939
36. Vivekanandan P., Gobianand K., Priya S., Vijayalakshmi P., and Karthikeyan S. Protective effect of picroliv against hydrazine-induced hyperlipidemia and hepatic steatosis in rats. Drug Chem Toxicol 30 (2007) 241-252
37. Gao H., and Zhou Y.W. Inhibitory effect of picroside II on hepatocyte apoptosis. Acta Pharmacol Sin 26 (2005) 729-736
38. Li T., Liu J.W., Zhang X.D., Guo M.C., and Ji G. The neuroprotective effect of picroside II from hu-huang-lian against oxidative stress. Am J Chin Med 35 (2007) 681-691
39. Shi X.Y., Hou F.F., Niu H.X., et al. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 149 (2008) 1829-1839
40. De C.R., Cipollone F., Filardo F.P., et al. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation 106 (2002) 2543-2549
41. Guo Z.J., Niu H.X., Hou F.F., et al. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 10 (2008) 1699-1712
42. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150